Shenzhen Hepalink Pharmaceutical Group

Resverlogix Corp. is a late-stage clinical biotechnology company based in Calgary, Canada, focused on developing innovative therapeutics for various severe health conditions. The company's primary product, apabetalone, is a first-in-class small molecule and selective bromodomain and extra-terminal (BET) inhibitor currently undergoing Phase III clinical trials. This drug aims to address cardiovascular diseases, chronic kidney disease, neurodegenerative disorders, and diabetes, among other indications. In addition to apabetalone, Resverlogix is advancing several development programs, including technologies targeting vascular inflammation and Alzheimer's disease. The NexVas platform, which has progressed through initial safety trials, focuses on reducing cardiovascular risk by enhancing ApoA-I levels. Other research initiatives include therapeutics designed for use with medical devices and preclinical projects targeting severe proliferative diseases. Overall, Resverlogix is committed to addressing unmet medical needs in chronic conditions through its diverse pipeline of therapeutic candidates.

OncoQuest Inc. is a biotechnology company based in Edmonton, Canada, founded in 2015. As a subsidiary of Quest PharmaTech, Inc., OncoQuest focuses on developing immunotherapeutic products aimed at treating cancer. The company has assembled a portfolio of bioactive technologies, including human and xenotypic monoclonal antibodies of the IgG and IgE classes, which are designed to induce tumor-specific immunity. With several lead components backed by clinical track records and extensive development dossiers, OncoQuest aims to integrate these therapies into combinatorial immuno-oncology treatment strategies. By exploring the therapeutic potential of antibodies in conjunction with other immune-modulating drugs, OncoQuest seeks to enhance clinical outcomes for cancer patients.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Shanghai Labway Clinical Laboratory Co., Ltd. is a prominent provider of in vitro diagnostic products and medical laboratory services, founded in 1993 and headquartered in Shanghai, China. The company specializes in a wide range of health management solutions, including genetic testing, clinical microbiology, blood and pathology testing, and cytopathological diagnosis. Labway focuses on optimizing resource allocation for healthcare institutions, aiming to reduce costs and risks while enhancing efficiency and patient satisfaction. By offering these comprehensive testing services, Labway supports public healthcare management and contributes to improved health outcomes.

OncoQuest Inc. is a biotechnology company based in Edmonton, Canada, founded in 2015. As a subsidiary of Quest PharmaTech, Inc., OncoQuest focuses on developing immunotherapeutic products aimed at treating cancer. The company has assembled a portfolio of bioactive technologies, including human and xenotypic monoclonal antibodies of the IgG and IgE classes, which are designed to induce tumor-specific immunity. With several lead components backed by clinical track records and extensive development dossiers, OncoQuest aims to integrate these therapies into combinatorial immuno-oncology treatment strategies. By exploring the therapeutic potential of antibodies in conjunction with other immune-modulating drugs, OncoQuest seeks to enhance clinical outcomes for cancer patients.

Cytovance Biologics, Inc. is a biopharmaceutical contract manufacturing organization based in Oklahoma City, Oklahoma, specializing in the production of therapeutic proteins and antibodies through mammalian cell culture and microbial fermentation. Founded in 2003, the company offers a range of services including cell line selection, process development, purification, and fill/finish operations, all adhering to current Good Manufacturing Practices (cGMP). Additionally, Cytovance provides analytical development, qualification, and regulatory support, as well as project management and quality assurance services. Its state-of-the-art facilities are FDA inspected, enabling the company to serve biopharmaceutical clients in the United States effectively. As of 2015, Cytovance Biologics operates as a subsidiary of Hepalink USA Inc.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Scientific Protein Laboratories LLC engages in manufacturing active pharmaceutical ingredients (APIs) for pharmaceutical, veterinary, and food industries worldwide. It offers heparin products, pancreatic enzyme products, derivative, blends, and custom specifications. The company also provides contract biopharmaceutical development and manufacturing services, including natural products extraction, fermentation and purification, analytical support, and heparin derivatives production. In addition, it supports its clients in various aspects of regulatory compliance, including providing CMC sections of IND, NDA, and aNDA; and offers process validation and equipment qualification services in support of its customers’ regulatory filings. The company was founded in 1976 and is based in Waunakee, Wisconsin.